60th American Society of Haematology Annual Meeting (ASH) Research Highlights

OPTIMISING CURRENT TREATMENTS The number of drugs available as myeloma treatment has grown significantly over the last two decades with discovery and approval of immunomodulatory drugs (thalidomide, lenalidomide (Revlimid®) and pomalidomide (Imnovid®)), proteasome inhibitors (bortezomib (Velcade®), cafilzomib (Kyprolis®) and ixazomib (Ninlaro®)), histone deacetylase inhibitors (panobinostat) and monoclonal antibody drugs (daratumumab (Darzalex®) and elotuzumab (Empliciti®)). However,…

February 11, 2019

Details

Benign monoclonal gammopathy: how benign is it?

Speaker: Prof Angela Dispenzieri, Mayo Clinic, USA

February 22, 2016

Details

Molecular subtyping in myeloma

Speaker: Dr Martin Kaiser, The Institute of Cancer Research

February 22, 2016

Details

How to manage high risk myeloma

Speaker: Dr Matthew Jenner, University Hospital Southampton NHS Foundation Trust

February 22, 2016

Details

The place of newer imaging techniques in multiple myeloma

Speaker: Dr Andrew Chantry, Sheffield Teaching Hospitals NHS Foundation Trust

February 8, 2016

Details

Stem cell transplantation in myeloma

Speaker: Prof Gordon Cook, Section of Experimental Haematology, University of Leeds

February 8, 2016

Details

Management of spinal myeloma disease – are we still failing the patient?

Speaker: Mr Sean Molloy, Royal National Orthopaedic Hospital, London

February 8, 2016

Details

UKMF Autumn Day 2013: What do we know about myeloma in elderly patients from trials and observational studies?

Speaker: Prof Heinz Ludwig, Wilhelminenhospital, Vienna. Austria

August 4, 2014

Details

UKMF Autumn Day 2013: The role of cytogenetics in elderly patients with myeloma

Speaker: Dr Faith Davies, Royal Marsden Hospital and The Institute of Cancer Research, London.

August 4, 2014

Details

UKMF Autumn Day 2013: The challenges of managing myeloma in the elderly

Speaker: Dr Stella Bowcock, Princess Royal Hospital, Orpington

August 4, 2014

Details